Online inquiry

IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1960MR)

This product GTTS-WQ1960MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLITRK6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_032229.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84189
UniProt ID Q9H5Y7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1960MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12878MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ11847MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ12111MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ9823MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ9574MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ10178MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ14513MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ3124MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW